$RAPT
RAPT Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000156459022019387 Filed on May 11, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $641.0K $1.222M
YoY Change -47.55% 30.7%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.748M $4.010M
YoY Change 18.4% 21.88%
% of Gross Profit
Research & Development $16.67M $13.77M
YoY Change 21.05% 28.91%
% of Gross Profit
Depreciation & Amortization $261.0K $280.0K
YoY Change -6.79% 40.0%
% of Gross Profit
Operating Expenses $21.42M $17.78M
YoY Change 20.44% 27.28%
Operating Profit -$20.78M -$16.56M
YoY Change 25.46% 27.03%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $309.0K $47.00K
YoY Change 557.45% -65.19%
Pretax Income -$20.47M -$16.51M
YoY Change 23.94% 28.0%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$20.47M -$16.51M
YoY Change 23.94% 25.69%
Net Earnings / Revenue -3193.14% -1351.39%
Basic Earnings Per Share -$0.69
Diluted Earnings Per Share -$692.1K -$664.7K
COMMON SHARES
Basic Shares Outstanding 29.57M 24.87M
Diluted Shares Outstanding 29.57M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $173.0M $98.40M
YoY Change 75.82% -28.8%
Cash & Equivalents $32.42M $24.72M
Short-Term Investments $140.6M $73.70M
Other Short-Term Assets $2.656M $4.200M
YoY Change -36.76% 13.51%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $175.7M $102.6M
YoY Change 71.21% -30.15%
LONG-TERM ASSETS
Property, Plant & Equipment $2.629M $2.900M
YoY Change -9.34% -19.58%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $2.933M $400.0K
YoY Change 633.25% 2.83%
Total Long-Term Assets $11.88M $3.300M
YoY Change 260.12% -17.4%
TOTAL ASSETS
Total Short-Term Assets $175.7M $102.6M
Total Long-Term Assets $11.88M $3.300M
Total Assets $187.5M $105.9M
YoY Change 77.1% -29.82%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.936M $3.100M
YoY Change -37.55% -9.06%
Accrued Expenses $8.276M $4.500M
YoY Change 83.91% 17.43%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $12.36M $11.10M
YoY Change 11.35% -17.42%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $7.353M $3.100M
YoY Change 137.19% -43.64%
Total Long-Term Liabilities $7.353M $3.100M
YoY Change 137.19% -43.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $12.36M $11.10M
Total Long-Term Liabilities $7.353M $3.100M
Total Liabilities $19.71M $14.28M
YoY Change 38.02% -24.83%
SHAREHOLDERS EQUITY
Retained Earnings -$231.4M
YoY Change 32.14%
Common Stock $323.2M
YoY Change 5.27%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $167.8M $91.64M
YoY Change
Total Liabilities & Shareholders Equity $187.5M $105.9M
YoY Change 77.06% -29.8%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income -$20.47M -$16.51M
YoY Change 23.94% 25.69%
Depreciation, Depletion And Amortization $261.0K $280.0K
YoY Change -6.79% 40.0%
Cash From Operating Activities -$15.58M -$13.91M
YoY Change 11.99% 59.06%
INVESTING ACTIVITIES
Capital Expenditures $149.0K $227.0K
YoY Change -34.36% 131.63%
Acquisitions
YoY Change
Other Investing Activities $23.99M $12.64M
YoY Change 89.76% -126.96%
Cash From Investing Activities $23.84M $12.41M
YoY Change 92.06% -126.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $1.180M
YoY Change -98.31%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 132.0K 1.301M
YoY Change -89.85% -98.14%
NET CHANGE
Cash From Operating Activities -15.58M -13.91M
Cash From Investing Activities 23.84M 12.41M
Cash From Financing Activities 132.0K 1.301M
Net Change In Cash 8.391M -198.0K
YoY Change -4337.88% -101.4%
FREE CASH FLOW
Cash From Operating Activities -$15.58M -$13.91M
Capital Expenditures $149.0K $227.0K
Free Cash Flow -$15.73M -$14.14M
YoY Change 11.25% 59.87%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2015Q2 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2015Q2 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6322000
CY2021Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
1016000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1481000
CY2022Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
22000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12360000
CY2021Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
2150000
CY2021Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
511000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7112000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4748000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4012000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20468000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-201000
CY2022Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-710000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-21379000
CY2022Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.69
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29572467
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
186380000
CY2022Q1 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
132000
CY2022Q1 us-gaap Stock Issued During Period Value Share Based Compensation
StockIssuedDuringPeriodValueShareBasedCompensation
2702000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20468000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
167835000
CY2021Q1 rapt Stock Issued During Period Value Employee Stock Plans
StockIssuedDuringPeriodValueEmployeeStockPlans
121000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
38000
CY2021Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-50000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16514000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
91641000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-20468000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-16514000
CY2022Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
341000
CY2021Q1 us-gaap Investment Income Amortization Of Premium
InvestmentIncomeAmortizationOfPremium
218000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
261000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
280000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2702000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2687000
CY2022Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
201000
CY2021Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-38000
CY2022Q1 rapt Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
428000
CY2021Q1 rapt Non Cash Operating Lease Expense
NonCashOperatingLeaseExpense
0
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-652000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
112000
CY2022Q1 rapt Increase Decrease In Deferred Rent Current And Noncurrent
IncreaseDecreaseInDeferredRentCurrentAndNoncurrent
0
CY2021Q1 rapt Increase Decrease In Deferred Rent Current And Noncurrent
IncreaseDecreaseInDeferredRentCurrentAndNoncurrent
-28000
CY2022Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-543000
CY2021Q1 us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
0
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-15578000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-13910000
CY2022Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
6055000
CY2021Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
15734000
CY2022Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
30041000
CY2021Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
28372000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
149000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
227000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
23837000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
12411000
CY2022Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
132000
CY2021Q1 us-gaap Proceeds From Stock Plans
ProceedsFromStockPlans
121000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
132000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1301000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
8391000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-198000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32418000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
24720000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6585000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2022Q1 us-gaap Nature Of Operations
NatureOfOperations
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1. Organization </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Description of the Business </p> <p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RAPT Therapeutics, Inc. (“RAPT” or the “Company”) is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing and commercializing oral small molecule therapies for patients with significant unmet needs in inflammatory diseases and oncology. Utilizing its proprietary drug discovery and development engine, the Company develops highly selective small molecules that are designed to modulate the critical immune responses underlying these diseases.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is located in South San Francisco, California.   </p>
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1553000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2109000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2183000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2259000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2137000
CY2018Q2 rapt Increased Area Of Leased Premises
IncreasedAreaOfLeasedPremises
36754
CY2018Q2 rapt Lessee Operating Lease Extended Lease Term
LesseeOperatingLeaseExtendedLeaseTerm
2026-11
CY2022Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
172908000
CY2022Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
945000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
171963000
CY2021Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
188520000
CY2021Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
235000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
188285000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities Within One Year Fair Value
AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
147431000
CY2022Q1 us-gaap Available For Sale Securities Debt Maturities After One Through Five Years Fair Value
AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
24532000
CY2022Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
171963000
CY2018Q2 rapt Additional Square Feet Area Of Laboratory And Office Facilities Under Lease
AdditionalSquareFeetAreaOfLaboratoryAndOfficeFacilitiesUnderLease
6378
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10534000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
10425000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7905000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
7684000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2629000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2741000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
300000
CY2022Q1 rapt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
5220000
CY2021Q4 rapt Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
2205000
CY2022Q1 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
2359000
CY2021Q4 us-gaap Workers Compensation Liability Current
WorkersCompensationLiabilityCurrent
3652000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
580000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
415000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
117000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
54000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8276000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6326000
CY2015Q2 rapt Operating Lease Expiration Year
OperatingLeaseExpirationYear
2022-05
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
10241000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
1648000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8593000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
6322000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1481000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
7112000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
8593000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
100000
CY2021Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
500000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y6M29D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-20468000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-16514000
CY2022Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
29572467
CY2021Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
24844946
CY2022Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
CY2021Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.66
CY2022Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6452915
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2702000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2687000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
24500000
CY2022Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P3Y
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2810348
CY2021Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2060385

Files In Submission

Name View Source Status
0001564590-22-019387-index-headers.html Edgar Link pending
0001564590-22-019387-index.html Edgar Link pending
0001564590-22-019387.txt Edgar Link pending
0001564590-22-019387-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
rapt-10q_20220331.htm Edgar Link pending
rapt-10q_20220331_htm.xml Edgar Link completed
rapt-20220331.xsd Edgar Link pending
rapt-20220331_cal.xml Edgar Link unprocessable
rapt-20220331_def.xml Edgar Link unprocessable
rapt-20220331_lab.xml Edgar Link unprocessable
rapt-20220331_pre.xml Edgar Link unprocessable
rapt-ex311_6.htm Edgar Link pending
rapt-ex312_7.htm Edgar Link pending
rapt-ex321_8.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending